Summary:
The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n=5), chronic myelomonocytic leukemia (CMML) (n=8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n=7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%–67%), and disease-free survival 37% (95% CI 17–58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Harris NL, Jaffe ES, Diebold J et al. World Health Organization classication of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting – Airlie house, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.
Montefusco E, Alimena G, Coco L et al. Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 1992; 65: 17–21.
Kantarjian HM, Kurzrock R, Talpaz M . Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol/Oncol Clin N Am 1990; 4: 389–404.
Hessling J, Kroger, Werner M et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769–772.
Przepiorka D, Giralt S, Khouri I et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24–28.
Anderson JE, Sale G, Appelbaum FR et al. Allogeneic marrow transplantation for primary myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010–1016.
Singhal S, Powles R, Treleaven J et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16: 743–746.
Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220–226.
O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822–1826.
Guardiola P, Esperou H, Cazals-Hatem D et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997; 98: 1004–1009.
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.
Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Prentice RL, Kalbfleisch JD . The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554.
Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
Reilly JT . Pathogenesis and management of idiopathic myelofibrosis. Bailliere's Clin Haematol 1998; 11: 751–767.
Rajantie J, Sale GE, Deeg HJ et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986; 67: 1693–1697.
Creemers GJ, Lowenberg B, Hagenbeek A . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82: 772–773.
Soll E, Massumoto C, Clift RA et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667–4673.
Onida F, Kantarjian HM, Smith TL et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.
Fenaux P, Beuscart R, Lai JL et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1998; 6: 1417–1424.
Tefferi A, Hoagland HC, Therneau TM, Pierre RV . Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64: 1246–1254.
Wattel E, Guerci A, Hecquet B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480–2487.
Beran M, Kantarjian H, O’Brien S et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473–2479.
Zang DY, Deeg HJ, Gooley T et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110: 217–222.
Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.
Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Progr) 2001; 375–391.
Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.
Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mittal, P., Saliba, R., Giralt, S. et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 33, 1005–1009 (2004). https://doi.org/10.1038/sj.bmt.1704472
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704472
Keywords
This article is cited by
-
EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
Bone Marrow Transplantation (2024)
-
High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
Bone Marrow Transplantation (2022)
-
Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO
Current Hematologic Malignancy Reports (2019)
-
Treatment of chronic myelomonocytic leukemia
memo - Magazine of European Medical Oncology (2016)
-
Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update
Current Hematologic Malignancy Reports (2015)